去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病的疗效观察

Idarubicin combined with cytarabine as induction therapy in patients with acute myeloid leukemia

目的:评价去甲氧柔红霉素(IDA)联合阿糖胞苷(Ara-C)(IA方案)治疗急性髓系白血病(AML)的疗效及不良反应。方法:50例AML患者,年龄10-61岁(中位年龄38岁),男27例,女23例。诱导化疗方案为IDA 10mg.m-2.d-1,d1-3;Ara-C 100mg.m-2.d-1,d1-7。结果:完全缓解率达86%,诱导化疗期间未发生早期死亡。不良反应主要为粒细胞缺乏所致的感染及血小板减少所致的出血。结论:IDA-A方案作为AML的诱导缓解化疗,安全、有效,具有较高的CR率。

Objective：To evaluate the efficacy and toxicity of idarubicin combined with cytarabine as inducation chemotherapy for patients with acute myeloid leukemia. Methods ：Total of 50 AML patients were enrolled,27 patients were male,23 patients were female,with age ranging from 10 to 61 years old（ median,38 years old）. The inducation therapy scheme was idarubicin（ 10mg/d, d1-3 ） and cytarabine （ 100mg · m -2 · d -1 , d1 _7 ）. Results：43 （ 86% ） pa- tients achieved complete remission. No fatality was observed during inducation. Infections due to neutropenia and hemorrhage due to thrombocytopenia were main adverse effects. Conclusion： Idarubicin combined with cytarabine as inducation therapy for AML is safe and effective, and has high CR rate.